Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Fanciulli C
  • Berenguer J
  • Busca C
  • Vivancos MJ
  • Téllez MJ
  • Domínguez L
  • Domingo P
  • Navarro J
  • Santos J
  • Iribarren JA
  • Morano L
  • Artero A
  • Moreno J
  • Rivero-Román A
  • Santos I
  • Giner L
  • Armiñanzas C
  • Manzardo C
  • Cifuentes C
  • García C
  • Galindo MJ
  • Ferrero OL
  • Sanz J
  • de la Fuente B
  • Rodríguez C
  • Gaspar G
  • Pérez L
  • Losa JE
  • Force L
  • Veloso S
  • Martínez-Alfaro E
  • Jarrín I
  • De Miguel M
  • González Garcia J
  • GeSIDA 8514 Study Group

Grupos

Abstract

OBJECTIVES: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. METHODS: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. RESULTS: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). CONCLUSIONS: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.

© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.

Datos de la publicación

ISSN/ISSNe:
1464-2662, 1468-1293

HIV MEDICINE  WILEY

Tipo:
Article
Páginas:
705-716
PubMed:
35037379
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,936 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 20

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • HIV infection/*epidemiology; coinfection/*epidemiology; hepatitis C/drug therapy/*epidemiology

Cita

Compartir